competent dh5α e coli Search Results


e. coli strains dh5α and bl-21 (λce6)  (Shanghai DingGuo Biotech Co)
90
Shanghai DingGuo Biotech Co e. coli strains dh5α and bl-21 (λce6)
E. Coli Strains Dh5α And Bl 21 (λce6), supplied by Shanghai DingGuo Biotech Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/competent+dh5%CE%B1+e+coli/competent+dh5%CE%B1+e++coli+cells/pmc05172407-127-6-11
Average 90 stars, based on 1 article reviews
e. coli strains dh5α and bl-21 (λce6) - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
competent dh5α ( e. coli ) cells  (GATC Biotech)
90
GATC Biotech competent dh5α ( e. coli ) cells
Can2 protects against MGE in vivo . ( A ) Plasmid challenge assay of mycobacterial type III-A system in <t>E.</t> <t>coli</t> host. E. coli cells harbouring the mycobacterial type III-A interference complex Csm1-5 and TetR targeting spacer were transformed with plasmid containing TsuCan2 effector and tetracycline-resistance gene (Wild-type). Other strains are indicated as ‘No Can2’ where the TsuCan2 is absent, ‘Cyclase variant’ where the interference complex is unable to produce cOA and ‘No targeting crRNA’ where the TetR targeting spacer is replaced with a spacer targeting pUC19 MCS. A 10-fold dilution series of the transformation mixture was applied onto tetracycline selective plates to determine the number of viable transformants. ( B ) Growth curves of E. coli cells harbouring the interference complex and phage P1 lpa gene-targeting spacer supplemented with TsuCan2 effector (indicated as Wild-type). Cells were grown in LB broth in a 96-well plate with shaking at 37°C and infected with phage P1 at a MOI of ∼1. OD 595 of the culture was measured every 15 min to plot against time over the 16 h incubation. Other strains are indicated as ‘Cyclase variant’ (green) where the interference complex is unable to produce cOA molecules; ‘No Lpa target’ (black) where lpa gene-targeting spacer is replaced with a spacer targeting pUC19 (MCS); ‘Can2 E302A/K304A’ (grey) which is a TsuCan2 nuclease variant. ‘Control’ (purple) represents wild-type cells (orange) incubated without phage infection under the same conditions. Data points represent the mean of eight experimental replicates (four biological replicates with two technical replicates each) with the standard deviation shown. ( C ) The OD 595 values of all strains after 4 and 10 h growth are shown, coloured as in panel B. Statistical analysis was carried out with RStudio using the unpaired Welch two sample test to calculate P -values. NS (not significant) indicates P -values > 0.05 and *** indicates P -values < 1E–05.
Competent Dh5α ( E. Coli ) Cells, supplied by GATC Biotech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/competent+dh5%CE%B1+e+coli/competent+dh5%CE%B1+++e++coli+++cells/pmc07969007-38-0-19
Average 90 stars, based on 1 article reviews
competent dh5α ( e. coli ) cells - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
neb 5-alpha competent e. coli  (New England Biolabs)
96
New England Biolabs neb 5-alpha competent e. coli
Can2 protects against MGE in vivo . ( A ) Plasmid challenge assay of mycobacterial type III-A system in <t>E.</t> <t>coli</t> host. E. coli cells harbouring the mycobacterial type III-A interference complex Csm1-5 and TetR targeting spacer were transformed with plasmid containing TsuCan2 effector and tetracycline-resistance gene (Wild-type). Other strains are indicated as ‘No Can2’ where the TsuCan2 is absent, ‘Cyclase variant’ where the interference complex is unable to produce cOA and ‘No targeting crRNA’ where the TetR targeting spacer is replaced with a spacer targeting pUC19 MCS. A 10-fold dilution series of the transformation mixture was applied onto tetracycline selective plates to determine the number of viable transformants. ( B ) Growth curves of E. coli cells harbouring the interference complex and phage P1 lpa gene-targeting spacer supplemented with TsuCan2 effector (indicated as Wild-type). Cells were grown in LB broth in a 96-well plate with shaking at 37°C and infected with phage P1 at a MOI of ∼1. OD 595 of the culture was measured every 15 min to plot against time over the 16 h incubation. Other strains are indicated as ‘Cyclase variant’ (green) where the interference complex is unable to produce cOA molecules; ‘No Lpa target’ (black) where lpa gene-targeting spacer is replaced with a spacer targeting pUC19 (MCS); ‘Can2 E302A/K304A’ (grey) which is a TsuCan2 nuclease variant. ‘Control’ (purple) represents wild-type cells (orange) incubated without phage infection under the same conditions. Data points represent the mean of eight experimental replicates (four biological replicates with two technical replicates each) with the standard deviation shown. ( C ) The OD 595 values of all strains after 4 and 10 h growth are shown, coloured as in panel B. Statistical analysis was carried out with RStudio using the unpaired Welch two sample test to calculate P -values. NS (not significant) indicates P -values > 0.05 and *** indicates P -values < 1E–05.
Neb 5 Alpha Competent E. Coli, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/competent+dh5%CE%B1+e+coli/NEB+5-alpha+Competent+E%2E+coli/custom%40c2988%4028829124
Average 96 stars, based on 1 article reviews
neb 5-alpha competent e. coli - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier

Image Search Results


Can2 protects against MGE in vivo . ( A ) Plasmid challenge assay of mycobacterial type III-A system in E. coli host. E. coli cells harbouring the mycobacterial type III-A interference complex Csm1-5 and TetR targeting spacer were transformed with plasmid containing TsuCan2 effector and tetracycline-resistance gene (Wild-type). Other strains are indicated as ‘No Can2’ where the TsuCan2 is absent, ‘Cyclase variant’ where the interference complex is unable to produce cOA and ‘No targeting crRNA’ where the TetR targeting spacer is replaced with a spacer targeting pUC19 MCS. A 10-fold dilution series of the transformation mixture was applied onto tetracycline selective plates to determine the number of viable transformants. ( B ) Growth curves of E. coli cells harbouring the interference complex and phage P1 lpa gene-targeting spacer supplemented with TsuCan2 effector (indicated as Wild-type). Cells were grown in LB broth in a 96-well plate with shaking at 37°C and infected with phage P1 at a MOI of ∼1. OD 595 of the culture was measured every 15 min to plot against time over the 16 h incubation. Other strains are indicated as ‘Cyclase variant’ (green) where the interference complex is unable to produce cOA molecules; ‘No Lpa target’ (black) where lpa gene-targeting spacer is replaced with a spacer targeting pUC19 (MCS); ‘Can2 E302A/K304A’ (grey) which is a TsuCan2 nuclease variant. ‘Control’ (purple) represents wild-type cells (orange) incubated without phage infection under the same conditions. Data points represent the mean of eight experimental replicates (four biological replicates with two technical replicates each) with the standard deviation shown. ( C ) The OD 595 values of all strains after 4 and 10 h growth are shown, coloured as in panel B. Statistical analysis was carried out with RStudio using the unpaired Welch two sample test to calculate P -values. NS (not significant) indicates P -values > 0.05 and *** indicates P -values < 1E–05.

Journal: Nucleic Acids Research

Article Title: The CRISPR ancillary effector Can2 is a dual-specificity nuclease potentiating type III CRISPR defence

doi: 10.1093/nar/gkab073

Figure Lengend Snippet: Can2 protects against MGE in vivo . ( A ) Plasmid challenge assay of mycobacterial type III-A system in E. coli host. E. coli cells harbouring the mycobacterial type III-A interference complex Csm1-5 and TetR targeting spacer were transformed with plasmid containing TsuCan2 effector and tetracycline-resistance gene (Wild-type). Other strains are indicated as ‘No Can2’ where the TsuCan2 is absent, ‘Cyclase variant’ where the interference complex is unable to produce cOA and ‘No targeting crRNA’ where the TetR targeting spacer is replaced with a spacer targeting pUC19 MCS. A 10-fold dilution series of the transformation mixture was applied onto tetracycline selective plates to determine the number of viable transformants. ( B ) Growth curves of E. coli cells harbouring the interference complex and phage P1 lpa gene-targeting spacer supplemented with TsuCan2 effector (indicated as Wild-type). Cells were grown in LB broth in a 96-well plate with shaking at 37°C and infected with phage P1 at a MOI of ∼1. OD 595 of the culture was measured every 15 min to plot against time over the 16 h incubation. Other strains are indicated as ‘Cyclase variant’ (green) where the interference complex is unable to produce cOA molecules; ‘No Lpa target’ (black) where lpa gene-targeting spacer is replaced with a spacer targeting pUC19 (MCS); ‘Can2 E302A/K304A’ (grey) which is a TsuCan2 nuclease variant. ‘Control’ (purple) represents wild-type cells (orange) incubated without phage infection under the same conditions. Data points represent the mean of eight experimental replicates (four biological replicates with two technical replicates each) with the standard deviation shown. ( C ) The OD 595 values of all strains after 4 and 10 h growth are shown, coloured as in panel B. Statistical analysis was carried out with RStudio using the unpaired Welch two sample test to calculate P -values. NS (not significant) indicates P -values > 0.05 and *** indicates P -values < 1E–05.

Article Snippet: Competent DH5α ( E. coli ) cells were transformed with the construct and sequence integrity was confirmed by sequencing (GATC Biotech, Eurofins Genomics, DE).

Techniques: In Vivo, Plasmid Preparation, Transformation Assay, Variant Assay, Infection, Incubation, Control, Standard Deviation